Archived: 5th Winter Conference
on Medicinal & Biooriganic Chemistry

January 26th - 31st 2003

Steamboat Springs Resort, Colorado

Agenda

Sunday, January 26th 2003

Round Table Discussion on the Foreseeable Future of Medicinal & Bioorganic Chemistry

Program Chair: Gary L. Grunewald, University of Kansas

Paul S. Anderson retired VP Bristol Meyers Squibb & Company
Lester A. Mitscher University of Kansas
John G. Topliss Professor of Medicinal Chemistry, University of Michigan and formerly VP of Chemistry at Warner Lamber/Parke-Davis

Monday, January 27th 2003

C-H Activation: The New Generation

Program Chair: Victor Snieckus, Queen’s University

Howard Alper University of Ottawa

Metal Catalyzed Reactions of Pharmaceutical Value

Robert Bergman University of California

C-H Activation: The Last Generation Tries to Keep Up with the Next Generation

John Hartwig Yale University

Catalytic Regioselective Functionalization of Alkanes and Arenes with Borane Reagents

Victor Snieckus Queen’s University

C-H Activation. An Overview

Chemical Genomics in Drug Discovery

Program Chair: Daniel Flynn, Deciphera Pharmaceuticals

Daniel Flynn Deciphera Pharmaceuticals

Approaches and Opportunities in Chemical Genomics

Michael Foley Infinity Pharnaceuticals Inc

Chemical Genetics

Mark Murcko Vertex Pharmaceuticals Inc

Organizing Research by Gene Family

Victor G. Matassa Graffinity

Fragment-Based Diversity on Chemical Microarrays: Discovery from a Different Angle

Tuesday, January 28th 2003

New Developments in High-Throughput Screening Methodologies

Program Chair: Michael Rafferty, Pfizer Global Research & Development

Michael Rafferty Pfizer Global Research & Development

High Throughput Pharmacology in Drug Discovery

Sohail A. Qureshi PanVera Corporation

Cell-Based Assay Development Using GeneDriver

Huw Nash NeoGenesis Pharmaceuticals

ALIS: Ultra High Capacity Affinity Screening for Drug Discovery

 

Timm Jessen Evotec OAI

Increased exploitation of the chemical space through economic sensitivity screening

Innovations in Process & Scale-Up Chemistry

Program Chair: Tony Barrett, Imperial College /Mike Lipton, Pharmacia Corp.

Robert Osborne AstraZeneca

Optimisation by Design

Shari Taghavi CPC Germany Microreaction Technology

Innovation in Chemical Syntheses from Bench to Production

Dennis Curran University of Pittsburgh

Fluorous Methods in Synthesis of Small Molecules

Andy de Mello Imperial College

Microfluidic Routes to the Controlled Synthesis of Small Molecules

Peter Wassercheid University of Aachen

Germany Ionic Liquids: A New Concept for Synthesis in Pharmaceutical Chemistry and Fine Chemicals Productions

Wednesday, January 29th 2003

General Papers | Session I

Program Chair: Michael VanNieuwenhze, University of California – San Diego

Not Itemized

KEYNOTE

Program Chair: Chi-Huey Wong, Scripps Research Institute

Thursday, January 30

General Papers | Session II

Program Chair: Dennis Dean, Merck Research Institute

Not Itemized

Chemokine Receptor Antagonists – HIV Targets

Program Chair: Wieslaw M. Kazmierski, GlaxoSmithKline

Nathaniel R. Landau Infectious Disease Laboratory

The Salk Institute for Biological Studies Fusion Inhibitors: Closing the Door on HIV

Dr Paul Finke Department of Medicinal Chemistry Merck and Co

The Development of Potent, Orally Active Antagonists of the Human CCR5 Receptor as Anti-HIV Agents

Dr Hiromu Habashita ONO Pharmaceutical Co. Ltd Japan Medicinal Chemistry Research Labs

The Discovery of CCR5 Antagonists from GPCR Targeted Combinatorial Library

Dr Jay R. Tagat Schering-Plough Research Institute

The Discovery of Potent, Orally Bioavailable CCR5 Antagonists for the Potential Treatment of HIV Infection

Friday, January 31st 2003

Chemokine Receptor Antagonists – Inflammation Targets

Program Chair: Lihu Yang, Merck and Co.

Lihu Yang Merck and Co.

Chemokine Receptor Antagonism as Potential Therapeutic Targets in Inflammatory Diseases

Karen May Berlex Laboratories Inc.

Discovery of Selective, Potent, Orally Available CCR1 Receptor Antagonists

Huw Daview AstraZeneca

Optimization of Small Molecule CCR2b Antagonists

Jianming Bao Merck & Co.

Pyrrolidine Antagonists of the CCR3 Chemokine Receptors

Don Hansen Pharmacia Corporation

Evolution in Our Design of Selective Inhibitors of Human Nitric Oxide Synthases from Cyclic Amidines to Hybrid Iminohomopiperidinium Amino Acid

Media Sponsors